SCHEMBL2039941

SCHEMBL2039941

c1ccc2c(c1)oc1ccc(-c3ccc4oc5ccc(-c6ccc7oc8ccccc8c7c6)cc5c4c3)cc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.63
KDM4E B2RXH2 3/20 0.63
ALDH1A1 P00352 3/20 0.63
HPGD P15428 3/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
NPC1 O15118 2/20 0.63
RAB9A P51151 1/20 0.63
AHR P35869 2/20 0.57
PLA2G2A P14555 5/20 0.51
PLA2G4A P47712 5/20 0.51
MAOA P21397 3/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C19 P33261 1/20 0.50
GLA P06280 1/20 0.50
CYP3A4 P08684 1/20 0.50
PGAM1 P18669 1/20 0.50
CASP1 P29466 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15835969 1.00 MAPT (0.63) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL15835950 1.00 MAPT (0.63) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL10478418 1.00 MAPT (0.63) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL24171975 0.98 MAPT (0.61) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL20706697 0.98 MAPT (0.61) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL26311700 0.98 MAPT (0.61) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL1636494 0.96 MAPT (0.59) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL1636873 0.96 MAPT (0.59) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL804741 0.96 MAPT (0.59) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL1636486 0.96 MAPT (0.59) MAPTKDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11839140-B2 Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS UDC IRELAND LIMITED (IE) 2023-12-05 US disclosed
US-11839140-B2 Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS UDC IRELAND LIMITED (IE) 2023-12-05 US disclosed
US-11839140-B2 Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS UDC IRELAND LIMITED (IE) 2023-12-05 US disclosed
US-20230026258-A1 Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS UDC IRELAND LTD (IE) 2023-01-26 US disclosed
US-20230026258-A1 Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS UDC IRELAND LTD (IE) 2023-01-26 US disclosed
US-11444254-B2 Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDs UDC IRELAND LIMITED (IE) 2022-09-13 US disclosed
US-11358951-B2 Π(PI)-conjugated compound, organic electroluminescence element material, light-emitting material, light-emitting thin film, organic electroluminescence element, display device, and illumination device MERCK PATENT GMBH (DE) 2022-06-14 US disclosed
US-20210126207-A1 Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS UDC IRELAND LTD (IE) 2021-04-29 US disclosed
US-20210126207-A1 Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS UDC IRELAND LTD (IE) 2021-04-29 US disclosed
US-10916716-B2 Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS UDC IRELAND LIMITED (IE) 2021-02-09 US disclosed
US-20130032766-A1 METAL COMPLEXES COMPRISING DIAZABENZIMIDAZOLOCARBENE LIGANDS AND THE USE THEREOF IN OLEDS BASF SE (DE) 2013-02-07 US disclosed
US-20130032766-A1 METAL COMPLEXES COMPRISING DIAZABENZIMIDAZOLOCARBENE LIGANDS AND THE USE THEREOF IN OLEDS BASF SE (DE) 2013-02-07 US disclosed
US-20130032766-A1 METAL COMPLEXES COMPRISING DIAZABENZIMIDAZOLOCARBENE LIGANDS AND THE USE THEREOF IN OLEDS BASF SE (DE) 2013-02-07 US disclosed
EP-2513125-A1 METAL COMPLEXES COMPRISING DIAZABENZIMIDAZOL CARBENE-LIGANDS AND THE USE THEREOF IN OLEDS BASF SE (DE) 2012-10-24 EP disclosed
WO-2011157790-A1 ORGANIC ELECTRONIC DEVICES COMPRISING A LAYER OF A DIBENZOFURANE COMPOUND AND A 8-HYDROXYQUINOLINOLATO EARTH ALKALINE METAL, OR ALKALI METAL COMPLEX BASF SE (DE) 2011-12-22 WO disclosed
EP-2395573-A1 ORGANIC ELECTROLUMINESCENT ELEMENT, AND ILLUMINATION DEVICE AND DISPLAY DEVICE EACH COMPRISING THE ELEMENT Konica Minolta Holdings, Inc. (JP) 2011-12-14 EP disclosed
US-20110272687-A1 ORGANIC ELECTROLUMINESCENT ELEMENT, AND ILLUMINATION DEVICE AND DISPLAY DEVICE EACH COMPRISING THE ELEMENT KONICA MINOLTA HOLDINGS, INC. (JP) 2011-11-10 US disclosed
US-20110272687-A1 ORGANIC ELECTROLUMINESCENT ELEMENT, AND ILLUMINATION DEVICE AND DISPLAY DEVICE EACH COMPRISING THE ELEMENT KONICA MINOLTA HOLDINGS, INC. (JP) 2011-11-10 US disclosed
WO-2011073149-A1 METAL COMPLEXES COMPRISING DIAZABENZIMIDAZOL CARBENE-LIGANDS AND THE USE THEREOF IN OLEDS BASF SE (DE) 2011-06-23 WO disclosed
WO-2011073149-A1 METAL COMPLEXES COMPRISING DIAZABENZIMIDAZOL CARBENE-LIGANDS AND THE USE THEREOF IN OLEDS BASF SE (DE) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130032766-A1 METAL COMPLEXES COMPRISING DIAZABENZIMIDAZOLOCARBENE LIGANDS AND THE USE THEREOF IN OLEDS OCIAD1, OCIAD2, DRD2 MAPT 883/4885KDM4E 4587/4885ALDH1A1 2444/4885
US-20230026258-A1 Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS OCIAD1, OCIAD2, DRD2 MAPT 893/4885KDM4E 4573/4885ALDH1A1 2588/4885
US-11839140-B2 Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS OCIAD1, OCIAD2, DRD2 MAPT 893/4885KDM4E 4573/4885ALDH1A1 2588/4885
US-20210126207-A1 Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS OCIAD1, OCIAD2, DRD2 MAPT 893/4885KDM4E 4573/4885ALDH1A1 2588/4885
US-11444254-B2 Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDs OCIAD1, OCIAD2, DRD2 MAPT 893/4885KDM4E 4573/4885ALDH1A1 2588/4885
US-10916716-B2 Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS OCIAD1, OCIAD2, DRD2 MAPT 893/4885KDM4E 4573/4885ALDH1A1 2588/4885
US-11358951-B2 Π(PI)-conjugated compound, organic electroluminescence element material, light-emitting material, light-emitting thin film, organic electroluminescence element, display device, and illumination device ZYX, OCIAD2, DRD1 MAPT 3012/4885KDM4E 2680/4885ALDH1A1 1108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.